|07/30/16 07:06 AM||HC Stocks Outlines: Gilead Sciences, Inc. (NASDAQ:GILD ... - share market updates (press release)|
|07/29/16 11:18 AM||Top 5 Corporate Donors in Big Pharma (GILD, MRK)|
|07/29/16 11:18 AM||Gilead Sciences: A Hard Wind is Gonna Blow|
|07/29/16 10:58 AM||Biotech Stocks: The End of Political Risk? - |
|07/29/16 10:40 AM||Merck posts strong 2Q numbers, while building for long term - |
|07/29/16 10:15 AM||Why Key Analyst Sees More Headwinds for Gilead Sciences - |
|07/28/16 03:00 PM||Would Gilead Sciences, Inc. (GILD) Be Able to Survive Without Eminent HCV Franchise?|
|07/28/16 12:49 PM||U.S. biotech stocks win back investors in big July run - |
|07/28/16 07:06 AM||Gilead Sciences Inc A Great Opportunity Post Q2 Earnings - Amigobulls|
|07/28/16 02:18 AM||DMG MORI still meeting target forecasts Annual forecast 2016 reconfirmed in volatile market environment - [at noodls] - July 28, 2016 Sales revenues amounted to € 1,092.5 million (previous year: € 1,090.2 million) Order intake reached € 1,158.2 million (previous year: € 1,203.3 million) EBT was € 61.2 million (previous ...|
|07/27/16 06:01 PM||UK health service under fire over access to hepatitis C drugs - [Reuters - UK Focus] - British health authorities improperly restrict access to expensive new hepatitis C drugs that can cure the liver-destroying disease, patient groups and a leading medical journal charged on Thursday. Despite the clear benefits of the drugs, the National Health Service in England rations the drugs to just 10,000 people with the virus each year, campaigners said. The Hepatitis C Trust said it was now seeking a judicial review of NHS England's decision and the court is considering whether to grant permission for the case to go ahead.|
|07/27/16 04:27 PM||Maxim Anayst Raises Concerns for Gilead Sciences, Inc. (GILD) Following 2Q Earnings - Smarter Analyst|
|07/27/16 04:08 PM||Gilead Sciences Is Still a Buy - |
|07/27/16 02:33 PM||Gilead's Valuation Makes It a Screaming Buy - |
|07/27/16 04:19 AM||News Buzz - Gilead Sciences, Inc.(NASDAQ:GILD), JetBlue Airways Corporation(NASDAQ:JBLU) - NYSE Journal (press release)|
|07/27/16 04:19 AM||Analysts Trends to Watch: Gilead Sciences, Inc. (NASDAQ:GILD) , Thermo Fisher Scientific Inc (NYSE:TMO) - Street Updates|
|07/26/16 10:27 PM||Eyes Catching Biotech Stocks in Verities- Gilead Sciences (NASDAQ:GILD), Celgene (NASDAQ:CELG) - Seneca Globe|
|07/26/16 10:27 PM||Gilead Sciences, Inc. (NASDAQ:GILD) & Relypsa Inc (NASDAQ:RLYP) Hot Stock's Alert - Money News (press release)|
|07/26/16 10:27 PM||Analysts Rating updates about two Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , Edwards Lifesciences Corporation ... - Street Updates|
|07/26/16 10:27 PM||Gilead Sciences Inc. Earnings Decline 14% In Q2 - Nasdaq|
|07/26/16 10:27 PM||Gilead Sciences Inc. (GILD) Falls 8.47% for July 26 - Equities.com|
|07/26/16 04:24 PM||Gilead Sciences, Inc. (GILD) Gets Price Target Trimmed Following Guidance Adjustments|
|07/26/16 04:24 PM||Gilead (GILD) Beats on Q2 Earnings, Cuts 2016 Sales View|
|07/26/16 04:24 PM||Gilead Sciences Inc. (GILD) Is Falling After Guidance Lowered|
|07/26/16 04:24 PM||GILD, MBLY and UA stock used more than their fair share of red ink on Tuesday|
|07/26/16 02:51 PM||Harvoni Sales Declines Hurt Gilead Sciences Inc. in Q2 - Disappointing revenue and earnings for this big biotech stem from big drops in sales for its top drug, Harvoni.|
|07/26/16 11:49 AM||3 Key Takeaways Following Gilead Sciences' Second-Quarter Conference Call - Struggles in oncology and hepatitis C are overshadowing growth in HIV treatment. Gilead Sciences' troubles, however, could be short-term if its R&D program pans out.|
|07/26/16 09:58 AM||Gilead Sciences, Inc. (GILD): Catch This Falling Knife NOW - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p>
<p>GILD stock was hit hard on Tuesday, continuing the pain for healthcare. But I see Gilead Sciences as an opportunity to pounce on.</p>
<p>The post <a rel="nofollow" href="http://investorplace.com/2016/07/gilead-sciences-gild-stock-knife/">Gilead Sciences, Inc. (GILD): Catch This Falling Knife NOW</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
|07/26/16 08:45 AM||3 Big Stock Charts for Tuesday: AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD) and Sprint Corp (S) - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (ABBV), Gilead (GILD) and Sprint (S) are all moving today after their respective earnings reports. All three have additional profit potential for those queued into these technical pictures.
The post 3 Big Stock Charts for Tuesday: AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD) and Sprint Corp (S) appeared first on InvestorPlace.
|07/26/16 07:03 AM||Noteworthy Analyst Rating of Gilead Sciences, Inc. (NASDAQ:GILD) - The Voice Registrar|
|07/26/16 07:03 AM||Biotech Titan on Spike: Gilead Sciences Inc. (NASDAQ:GILD) Beats Wall Street Expectations Once Again- AbbVie Inc ... - Seneca Globe|
|07/26/16 07:03 AM||Price Target Review: Gilead Sciences Inc. (GILD) - News Oracle|
|07/26/16 06:41 AM||Stock Futures Flat as Federal Reserve Prepares to Meet - |
|07/26/16 06:37 AM||Wait On The DNC Before Going Long Biotech ETFs -
This week is a potentially troublesome one for biotechnology stocks and the related exchange traded funds. Not only are there a spate of big-name biotech earnings scheduled to roll in, but the Democratic National Convention is taking place in Philadelphia.
Gilead Sciences, Inc. (NASDAQ: GILD) got the earnings ball rolling after Monday's close and investors weren't pleased by the company's guidance.
Combine that with the fact that political volatility has been widely cited as a problem for the biotech sector dating back to last year, and it's easy to see why some market participants are waiting for this week's convention to conclude before initiating new long positions in ETFs such as the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB).
Related ...Full story available on Benzinga.com|
|07/26/16 05:55 AM||Gilead cuts 2016 sales forecast, cites hepatitis C drugs - Gilead Sciences lowered its full-year sales outlook, citing slower-than-expected demand for its hepatitis C drugs, and said profits fell 22 percent.|
|07/25/16 09:42 PM||7 Key Figures From Gilead Sciences' Q2 Earnings - Motley Fool - Motley Fool7 Key Figures From Gilead Sciences' Q2 EarningsMotley FoolGilead Sciences, Inc. (NASDAQ:GILD) is one of the biggest companies in biopharma, but that hasn't kept investors from selling its shares this year. Stiffening competition in the market for hepatitis C treatment has caused sales of its multibillion ...Gilead cuts 2016 sales forecast, cites hepatitis C drugsReutersGilead Is Back To Beating EstimatesSeeking AlphaGilead's high-flying hep C franchise comes down to earth, forcing a cut to 2016 guidanceFiercePharmaNasdaq -24/7 Wall St. -Investorplace.com -Investor's Business Dailyall 76 news articles »|
|07/25/16 09:23 PM||7 Key Figures From Gilead Sciences' Q2 Earnings - Gilead Sciences' Harvoni sales weighed on results, but the company's balance sheet strengthened.|
|07/25/16 05:40 PM||4 Stocks Moving In Monday's After-Hours Session -
U.S. stock markets closed down on Monday, accompanying oil prices, and ahead of a long slate of earnings calls and the Fed’s decision on interest rates.
Sophiris Bio Inc (NASDAQ: SPHS) rose 35.84 percent during the regular session, and continued to rise more than 5.2 percent in the after-hours session. No particular news seemed to be driving said spike, which looked like a technical move.
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) traded down ...Full story available on Benzinga.com|
|07/25/16 04:43 PM||Gilead second-quarter net profit falls 22 percent - July 25 (Reuters) - Gilead Sciences Inc said on
Monday its second-quarter net profit fell 22 percent, due mostly
to lower sales of its hepatitis C drug Harvoni.
|07/25/16 04:43 PM||UPDATE 1-Gilead cuts 2016 sales forecast, cites hepatitis C drugs - July 25 (Reuters) - Gilead Sciences Inc on Monday
lowered its full-year sales outlook, citing slower-than-expected
sales of its key hepatitis C drugs, and said second-quarter
profits fell 22 percent.
|07/25/16 04:25 PM||Gilead Misses Revenue Estimates, Cuts Guidance -
Gilead Sciences, Inc. (NASDAQ: GILD) released its Q2 results after market close on Monday. Revenues came in above Wall Street consensus expectations, however, the company lowered sales guidance, sending shares down 4 percent.
Gilead reported EPS of $3.08 and revenues of $7.776 billion. Analyst consensus had an EPS estimate ...Full story available on Benzinga.com|
|07/25/16 04:17 PM||HC Trending Hot Stocks: Medtronic PLC (NYSE:MDT) Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)|
|07/25/16 04:17 PM||Today's Stocks: MGIC Investment Corp. (NYSE:MTG), Gilead Sciences Inc. (NASDAQ:GILD), Crown Castle ... - KC Register|
|07/25/16 04:17 PM||Mix Momentum Detain Active Stocks: Gilead Sciences Inc. (NASDAQ:GILD), Gentex Corp. (NASDAQ:GNTX), Merck ... - Seneca Globe|
|07/25/16 04:17 PM||Baird's 2Q Earnings Preview: Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG) - Smarter Analyst|
|07/25/16 04:02 PM||GILEAD SCIENCES INC Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and Exh - |
|07/25/16 03:50 PM||[$$] Gilead Sales of Hepatitis C Drugs Fall 19% - |
|07/25/16 03:44 PM||BRIEF-Gilead Sciences Q2 non-GAAP earnings per share $3.08 - * Q2 Harvoni sales $ 2.56 billion versus $3.61 billion last
|07/25/16 03:44 PM||BRIEF-Gilead Sciences sets qtrly dividend of $0.47 per share - * Sets quarterly cash dividend of $0.47per share
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
|07/25/16 03:37 PM||After The Close: Gilead, Las Vegas Sands, Texas Instruments Earnings - |